Introducing nSTRIDE

Introducing nSTRIDE

The Regenerative Clinic launches nSTRIDE autologous protein injections for the relief of knee osteoarthritis

The Regenerative Clinic has added a new treatment called nSTRIDE Autologous Protein Injections to its portfolio of rejuvenating orthobiologic therapies. The nSTRIDE protein injection uses protein taken from the patient’s own body to treat osteoarthritis and other degenerative or trauma related musculoskeletal injuries.

nSTRIDE has been shown to provide pain relief in 70% patients with results recorded regularly throughout and up to 3 years following treatment. It is a day case procedure where blood is drawn from the patient’s arm, and then processed using a centrifuge that separates the platelet-rich plasma (PRP). The centrifuge further processes into a concentrated liquid protein. This solution is then injected back into the patient’s knee.

nSTRIDE adds to The Regenerative Clinic’s portfolio, which offers the latest advances in orthobiologic medicine. Simon Checkley, CEO, The Regenerative Clinic says; “Results to date with nSTRIDE are extremely impressive and we are proud to offer this very exciting treatment. Our mission is to continue to help people who are in the pervasive pain of osteoarthritis. nSTRIDE is a viable, safe and with treatment times of only an hour; a rapid treatment choice to reduce pain and delay the need for surgery. Our experienced team of 40 consultant surgeons and many more clinicians in six countries worldwide are dedicated to bringing people in pain the latest technologies in regenerative medicine.”

nSTRIDE has been the subject of a number of research papers which demonstrate good outcomes, especially for knee osteoarthritis. According to a recent study a 70% improvement in osteoarthritic knee pain was shown 2 years following a single injection.* The paper’s authors Kon E, Engebretsen L, Peter Verdonk P, Nehrer S and Filardo G, said; “A single intraarticular nSTRIDE APS injection is safe (similar to a saline injection) and continues to provide pain improvement at 1 year.” This measurement is based on the WOMAC scoring system, which is a much more stringent measurement than standard VAS scoring, so 70% is very positive.

nSTRIDE will be available at the flagship clinic at the Queen Anne Hospital in London’s Harley Street Medical area from March 2020, and at regional clinics to follow. Patients will be assessed by an expert consultant in their specific pathology to ascertain suitability for treatment.

The Regenerative Clinic has pioneered rejuvenating therapies around the world providing pioneering treatment for healing, pain relief and rejuvenation of joints and other tissues to restore mobility and function. Led by Professor Adrian Wilson the team of specialist Harley Street consultants, each one an expert in their own field (orthopaedic, radiology, gynaecological, spine, maxillofacial and cosmetic) have found that for the successful regeneration of tissues three components are important and need to be present. This includes a scaffold; cells that are able to reside within this scaffold; and the factor’s substances that allow the communication between the cells.

For further information on the treatment, please contact our helpful enquiry team on 0330 2233332 or email bookings@theregenerativeclinic.co.uk.


Leave a Reply

Your email address will not be published. Required fields are marked *

Get in touch

Find your clinic

We offer appointments nationwide and now working with partners abroad providing cutting edge Regenerative Medicine to patients in Dubai, Australia, Spain and Pakistan.

Sign-up to receive our recent news and the latest developments in regenerative medicine.

You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at info@theregenerativeclinic.co.uk. We will treat your information with respect. For more information about our privacy practices please visit our website. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.